Core Viewpoint - Pharming Group N.V. has received a positive opinion from the CHMP of the EMA recommending marketing authorization for Joenja® (leniolisib) for treating activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 12 years and older, marking a significant advancement in APDS care in Europe [1][3][6]. Company Overview - Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing innovative medicines for rare and life-threatening diseases, headquartered in Leiden, the Netherlands [10]. Product Information - Joenja® (leniolisib) is an oral small molecule PI3Kδ inhibitor, currently approved in the U.S., U.K., Australia, and Israel for patients aged 12 years and older with APDS, and in Japan for patients aged 4 years and older [8][4]. - The positive CHMP opinion is based on a Phase II/III clinical trial involving 31 patients, demonstrating a statistically significant impact on immune dysregulation and immunodeficiency [3][6]. Market Potential - If approved by the European Commission, Joenja would be the first treatment for APDS in the European Union, with centralized marketing authorization valid across all 27 EU Member States, Norway, Iceland, and Liechtenstein [2][6]. Clinical Insights - The clinical program for leniolisib has shown meaningful improvements in immune dysregulation and deficiency, suggesting it could significantly change the clinical outlook for patients with APDS [4][3]. - APDS affects approximately 1 to 2 individuals per million worldwide, and patients often experience a median diagnostic delay of 7 years [7][5].

Core Viewpoint - Pharming Group N.V. has received approval from Japan's Ministry of Health, Labour and Welfare for Joenja® (leniolisib), marking it as the first treatment for activated PI3K delta syndrome (APDS) in Japan and globally for children aged 4 to 11 [1][2][7] Company Overview - Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing innovative medicines for rare and life-threatening diseases, headquartered in Leiden, the Netherlands [11] Product Details - Joenja® (leniolisib) is an oral, selective PI3K delta inhibitor approved for patients aged 4 years and older, targeting APDS, a rare primary immunodeficiency [1][9] - The approval is based on positive Phase III clinical trial data demonstrating significant improvements in immune function and tolerability [4][9] Market and Distribution - OrphanPacific, Inc. will act as the Marketing Authorization Holder for Joenja in Japan, collaborating with Pharming for supply and distribution [2] - The launch of Joenja is contingent upon agreement with the MHLW regarding its National Health Insurance drug price [2] Clinical Significance - The approval of Joenja is a significant advancement for the APDS community in Japan, providing the first targeted treatment option for this rare disease [3][4] - The clinical trials included a global, randomized, placebo-controlled study and a Japanese open-label study, both showing improvements in lymphadenopathy and B cell function [4][5] Regulatory Pathway - The application for Joenja was evaluated under the Priority Review pathway after receiving Orphan Drug Designation from the MHLW in May 2023 [5]

Core Viewpoint - Pharming Group N.V. announced that the FDA has accepted its supplemental New Drug Application for leniolisib, aimed at treating children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), with a target action date of January 31, 2026 [1][7]. Group 1: FDA Approval Process - The supplemental New Drug Application is based on positive results from a Phase III study showing improvements in lymphadenopathy and naïve B cells over 12 weeks [2]. - The FDA has granted Priority Review status to the application, indicating that the treatment could offer significant improvements in effectiveness or safety for serious conditions [3]. Group 2: Disease Background - APDS is a rare primary immunodeficiency characterized by immune dysregulation and recurrent infections, often leading to severe complications such as lung damage and lymphoma [5]. - The condition affects approximately 1 to 2 individuals per million globally, and patients often experience a median diagnostic delay of 7 years [5]. Group 3: Treatment Details - Leniolisib is an oral PI3Kδ inhibitor, previously approved for patients aged 12 and older, and is the first targeted treatment for APDS [6][4]. - The drug has shown statistically significant improvements in clinical trials, and its safety and tolerability have been supported by long-term data [6]. Group 4: Future Developments - Leniolisib is currently under regulatory review in multiple regions, including the European Economic Area, Japan, and Canada, for its use in APDS [6]. - The company is also evaluating leniolisib in additional clinical trials for other primary immunodeficiencies with immune dysregulation [8].